BusinessDenali Therapeutics Announces Pricing of Initial Public OfferingBy Nasdaq OMXDec 8, 2017, 12:08 AM UTC
BusinessInspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017By Nasdaq OMXDec 7, 2017, 5:23 PM UTC
BusinessInspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPSBy Nasdaq OMXDec 5, 2017, 6:00 PM UTC
BusinessIn new survey of patients, Inspire examines clinical trials, genetic testingBy Nasdaq OMXDec 5, 2017, 5:00 PM UTC
BusinessAmarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson's disease with EltoprazineBy Nasdaq OMXDec 5, 2017, 12:45 PM UTC
BusinessInspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and VietnamBy Nasdaq OMXDec 4, 2017, 2:45 PM UTC
BusinessBeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in ChinaBy Nasdaq OMXDec 4, 2017, 12:00 PM UTC
BusinessBeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate SuperiorityBy Nasdaq OMXNov 30, 2017, 2:58 PM UTC
